Two Sigma Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-95,445
| Closed | -$505K | – | 2511 |
|
|
2025
Q1 | $505K | Sell |
95,445
-356,300
| -79% | -$1.88M | ﹤0.01% | 1775 |
|
|
2024
Q4 | $3.05M | Sell |
451,745
-38,155
| -8% | -$258K | 0.01% | 923 |
|
|
2024
Q3 | $3.23M | Buy |
489,900
+54,100
| +12% | +$357K | 0.01% | 862 |
|
|
2024
Q2 | $3.27M | Buy |
435,800
+250,700
| +135% | +$1.88M | 0.01% | 946 |
|
|
2024
Q1 | $1.85M | Buy |
185,100
+153,400
| +484% | +$1.53M | ﹤0.01% | 1270 |
|
|
2023
Q4 | $313K | Buy |
+31,700
| New | +$313K | ﹤0.01% | 2088 |
|
|
2023
Q2 | – | Sell |
-15,400
| Closed | -$103K | – | 2622 |
|
|
2023
Q1 | $103K | Buy |
+15,400
| New | +$103K | ﹤0.01% | 2380 |
|
|
2022
Q2 | – | Sell |
-40,100
| Closed | -$287K | – | 2853 |
|
|
2022
Q1 | $287K | Buy |
+40,100
| New | +$287K | ﹤0.01% | 2241 |
|